1. Home
  2. EXR vs ALNY Comparison

EXR vs ALNY Comparison

Compare EXR & ALNY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Extra Space Storage Inc

EXR

Extra Space Storage Inc

HOLD

Current Price

$132.23

Market Cap

30.3B

Sector

Real Estate

ML Signal

HOLD

Logo Alnylam Pharmaceuticals Inc.

ALNY

Alnylam Pharmaceuticals Inc.

HOLD

Current Price

$254.12

Market Cap

34.2B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
EXR
ALNY
Founded
1977
2002
Country
United States
United States
Employees
N/A
115
Industry
Real Estate Investment Trusts
Biotechnology: Pharmaceutical Preparations
Sector
Real Estate
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
30.3B
34.2B
IPO Year
2004
2004

Fundamental Metrics

Financial Performance
Metric
EXR
ALNY
Price
$132.23
$254.12
Analyst Decision
Buy
Strong Buy
Analyst Count
15
28
Target Price
$144.80
★ $471.00
AVG Volume (30 Days)
1.2M
★ 1.3M
Earning Date
04-28-2026
04-30-2026
Dividend Yield
★ 4.61%
N/A
EPS Growth
13.90
★ 206.88
EPS
2.39
★ 2.71
Revenue
★ $3,377,542,000.00
$1,037,418,000.00
Revenue This Year
N/A
$52.67
Revenue Next Year
$3.63
$31.48
P/E Ratio
★ $55.10
$94.23
Revenue Growth
3.70
★ 22.88
52 Week Low
$125.71
$197.81
52 Week High
$158.88
$495.55

Technical Indicators

Market Signals
Indicator
EXR
ALNY
Relative Strength Index (RSI) 33.05 53.41
Support Level $128.34 $236.00
Resistance Level $151.04 $272.08
Average True Range (ATR) 2.46 8.32
MACD -0.30 0.83
Stochastic Oscillator 16.13 79.31

Price Performance

Historical Comparison
EXR
ALNY

About EXR Extra Space Storage Inc

Extra Space Storage is a fully integrated real estate investment trust that owns, operates, and manages more than 4,200 self-storage properties in 43 states, with over 330 million net rentable square feet of storage space. Of these properties, approximately one half is wholly owned, while some facilities are owned through joint ventures and others are owned by third parties and managed by Extra Space Storage in exchange for a management fee.

About ALNY Alnylam Pharmaceuticals Inc.

Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam's commercial RNAi therapeutic products include Onpattro and Amvuttra (for hATTR amyloidosis), Givlaari (for acute hepatic porphyria), and Oxlumo (for primary hyperoxaluria type 1), all developed and commercialized by Alnylam. Plus, Leqvio (for hypercholesterolemia) and Qfitlia (for hemophilia A or B), which are being commercialized by Alnylam's partners, Novartis and Sanofi, respectively. It also has several clinical programs across various therapeutic areas, including cardio-metabolic diseases, neuroscience, and hematology.

Share on Social Networks: